Analysis Tools
mortality/aging
| N |
• homozygotes are viable, fertile and healthy under normal conditions, and display no differences in platelet activating factor (PAF)-induced lethality relative to wild-type mice (50% lethality at 200 g/kg)
|
|
• at 11-13 weeks, male homozygotes are hypersensitive to etoposide (but not vincristine) toxicity, as shown by increased mortality relative to wild-type mice
|
homeostasis/metabolism
|
• at 11-13 weeks, male homozygotes are hypersensitive to etoposide (but not vincristine) toxicity, as shown by increased mortality relative to wild-type mice
|
|
• at 11-13 weeks, male homozygotes are hypersensitive to etoposide (but not vincristine) toxicity, as shown by increased body weight loss relative to wild-type mice
|
immune system
|
• in vitro, bone marrow-derived mast cells (BMMCs) from mutant mice excrete significantly less LTC4 and accumulate more LTC4 intracellularly relative to wild-type BMMCs; no differences are noted in LTB4 excretion
|
|
• homozygotes show a significantly reduced inflammatory response to topical application arachidonic acid, as shown by reduced ear edema and decreased vascular permeability and extravasation of serum proteins relative to wild-type mice
• in contrast, homozygotes exhibit a normal inflammatory response to intradermal injection of LTC4 or topical application of phorbol ester (TPA)
|
hematopoietic system
|
• in vitro, bone marrow-derived mast cells (BMMCs) from mutant mice excrete significantly less LTC4 and accumulate more LTC4 intracellularly relative to wild-type BMMCs; no differences are noted in LTB4 excretion
|
